Michael J. Hanaway, MD

hanaway

Michael J. Hanaway, MD
Associate Professor of Surgery
Director, Renal Transplant Program

748 Lyons-Harrison Building
701 19th Street South
Birmingham, AL 35294

Phone: 205-934-2131

Board Certification  

American Board of Surgery -  June 10, 1998

 

Areas of Interest 

Kidney Transplantation

Pancreas Transplantation

Live Kidney Donation

Steroid Free Immunosuppression

Induction Therapy

Delayed Allograft Function.

Cancer in Transplantation

 

Education

University of Wisconsin, BS 1986

University of Wisconsin, MD 1991

University of Wisconsin Hospitals, Surgical Residency, 1997

Duke University, Research in Xenotransplantation, 1998

University of Wisconsin Hospitals, Transplant Fellowship, 1999-2000

 

Society Memberships

 

 

Diplomate, American Board of Surgery

American College of Surgeons

American Society of Transplantation

American Society of Transplant Surgeons

American Medical Association

Medical Society of Wisconsin

Medical Society of Ohio

Mont Reid Surgical Society of the University of Cincinnati

Central Surgical Society

 

Awards and Honors

 

2007, 2008 Best Doctors in America

 

Selected Publications

 

Hanaway MJ, Buell JF, Musat AI, Kalayoglu M. Graft Versus Host Disease in Solid Organ Transplantation. Graft 2001;4:205-208.

Hanaway MJ, Weber S, Buell JF, Trofe J, Alloway R, Beebe T, Gross T, Frist MR, Woodle ES.  Risk of recurrence and death from pre-existing cancers after transplantation.  Transplantation Reviews.2005;19(3);151-163.

Joseph F. Buell, Thomas M. Beebe, Michael J. Hanaway, Mark J. Thomas, Steven M. Rudich, E. Steve Woodle.  Transplant-Related Malignancies.  Transplantation of the Liver; Edition 5.  Elsevier.  (In Press)

 

Hanaway MJ, Weber S, Buell JF, Trofe J, Alloway R, Beebe T, Gross T, Frist MR, Woodle ES.  Risk of recurrence and death from pre-existing cancers after transplantation.  Transplantation Reviews.2005;19(3);151-163.

Hanaway MJ, Woodle ES, Mulgonkav S, Peddr R, Harrison G, Vandepulte K. Fitzsimmons N, First R., Holman V.  12 month results of a multicenter, randomized trial comparing three induction agents (Alemtuzumab, Thymoglobulin, and Basiliximah) with Tacrolimus, Mycophenolate, Mofetil and a rapid steroid withdrawal in renal transplantation.  American Journal of Transplantation.  2008: 8; 215